Depomed (DEPO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
RBC Reiterates Sector Perform Rating and $22 PT on Depomed (DEPO) Following 4Q Results, Ahead of 2/23 RBC Healthcare Conference
February 22, 2017 7:42 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Sector Perform rating and $22 price target on Depomed Inc. (NASDAQ: DEPO), suggesting the strategic outlook remains the focus, as the company reported 2016 fourth quarter revenue and EPS slightly above consensus. RBC Capital Markets will be hosting Depomed at the RBC Healthcare Conference on Thursday,... More
